摘要
目的:本研究旨在观察不同剂量重组人血管内皮抑制素(恩度)胸腔灌注治疗非小细胞肺癌恶性胸腔积液的疗效及安全性。方法:将2017年1月至2020年6月在邢台市第一医院胸外科住院的病例中选取的92例恶性胸腔积液患者分为A、B、C3组,均留置中心静脉导管,均在充分穿刺抽液或引流后给药。胸腔灌注不同剂量的恩度,并进行总有效率及安全性的比较。结果:A、B、C3组胸腔分别注入恩度30 mg、60 mg、90 mg;总有效率分别为65.5%、75.0%、83.9%,但差异无统计学意义。恩度治疗恶性胸腔积液总体疗效较好。研究结果还显示,不良反应并不随剂量的增加而增加。结论:肺癌恶性胸腔积液患者胸腔灌注不同浓度的恩度整体疗效较好。不同剂量恩度胸腔灌注的疗效差异无统计学意义,且不良反应的发生率并不随剂量的增加而增加。
Objective:To investigate the clinical efficacy and safety of different dosages of recombinant human endostatin(Rh-endostatin)in treatment of non-small cell lung cancer(NSCLC)with malignant pleural effusion(MPE)by intrapleural injection.Methods:Ninety-two cases of NSCLC patients with MPE admitted in the Department of Thoracic Surgery,the First Hospital of Xingtai from January 2017 to June 2020 were divided into 3 groups in this study.All the patients underwent thoracic close drainage via central venous catheters,different dosages of Rh-endostatin were administrated through the catheters,and clinical efficacy and safety were compared.Results:Total clinical efficacy rates for 30 mg,60 mg and 90 mg Rh-endostatin were 65.5%,75.0%and 83.9%,respectively,without statistical significance.Rh-endostatin had a good overall effect in the treatment of MPE of NSCLC.The results also revealed that the incidences of adverse events(AEs)were not increased with the increase of the dosage.Conclusions:Therapeutic effects of different dosages of Rh-endostatin in the treatment of MPE of NSCLC are not statistically different,and the increase of dosage does not raise the incidence of AEs.
作者
杨璞
李反念
豆瑞刚
曹万乐
刘扬
朱梓铭
高计林
刘军校
刘世伟
YANG Pu;LI Fannian;DOU Ruigang;CAO Wanle;LIU Yang;ZHU Ziming;GAO Jilin;LIU Junxiao;LIU Shiwei(Department of Thoracic Surgery,the First Hospital of Xingtai,Xingtai,Hebei 054001,China)
出处
《药学与临床研究》
2022年第4期339-342,共4页
Pharmaceutical and Clinical Research
关键词
非小细胞肺癌
恶性胸腔积液
恩度
胸腔灌注
Non-small cell lung cancer
Malignant pleural effusion
Recombinant human endostatin
Intrapleural injection
